Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$71.66
+1.2%
$73.09
$57.52
$132.26
$28.10B1.54.22 million shs2.86 million shs
Insulet Co. stock logo
PODD
Insulet
$260.71
+0.5%
$260.21
$160.19
$289.46
$18.31B1.3713,786 shs465,388 shs
ResMed Inc. stock logo
RMD
ResMed
$235.79
-0.1%
$221.92
$179.42
$263.05
$34.63B0.751.02 million shs1.19 million shs
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$334.75
$332.85
$157.00
$334.90
$12.57B0.88968,088 shsN/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%+4.47%+5.79%-18.13%-42.37%
Insulet Co. stock logo
PODD
Insulet
0.00%+5.64%+0.76%-5.50%+56.87%
ResMed Inc. stock logo
RMD
ResMed
0.00%+10.76%+7.25%-7.51%+8.13%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
0.00%0.00%0.00%0.00%+1.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DexCom, Inc. stock logo
DXCM
DexCom
4.9482 of 5 stars
4.54.00.04.74.12.51.9
Insulet Co. stock logo
PODD
Insulet
4.6199 of 5 stars
3.44.00.04.93.60.81.9
ResMed Inc. stock logo
RMD
ResMed
3.89 of 5 stars
2.31.03.34.62.11.71.3
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$99.0038.15% Upside
Insulet Co. stock logo
PODD
Insulet
2.82
Moderate Buy$292.0612.02% Upside
ResMed Inc. stock logo
RMD
ResMed
2.60
Moderate Buy$258.839.77% Upside
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SWAV, RMD, DXCM, and PODD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$274.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$247.00 ➝ $255.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$290.00 ➝ $285.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$286.00 ➝ $290.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$260.00 ➝ $248.00
4/21/2025
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$280.00 ➝ $269.00
4/16/2025
ResMed Inc. stock logo
RMD
ResMed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$265.00
4/10/2025
DexCom, Inc. stock logo
DXCM
DexCom
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$85.00
4/9/2025
DexCom, Inc. stock logo
DXCM
DexCom
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/21/2025
DexCom, Inc. stock logo
DXCM
DexCom
Cfra Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
3/19/2025
ResMed Inc. stock logo
RMD
ResMed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$280.00
(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B6.97$1.80 per share39.75$5.38 per share13.32
Insulet Co. stock logo
PODD
Insulet
$2.07B8.84$3.43 per share75.96$10.49 per share24.85
ResMed Inc. stock logo
RMD
ResMed
$5.02B6.90$9.35 per share25.23$35.77 per share6.59
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$787.97M15.95$4.31 per share77.61$20.02 per share16.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.4350.1129.132.3014.29%30.14%10.11%5/1/2025 (Estimated)
Insulet Co. stock logo
PODD
Insulet
$206.30M$5.7945.0352.463.6220.19%24.46%8.33%5/8/2025 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.02B$8.9127.8422.761.5325.34%26.17%18.60%N/A
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$147.28M$4.2878.2154.342.4320.75%24.79%11.95%N/A

Latest SWAV, RMD, DXCM, and PODD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Insulet Co. stock logo
PODD
Insulet
$0.81N/AN/AN/A$543.20 millionN/A
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33N/AN/AN/A$1.02 billionN/A
4/23/2025Q3 2025
ResMed Inc. stock logo
RMD
ResMed
$2.37$2.37N/A$2.48$1.28 billion$1.29 billion
2/20/2025Q4 2024
Insulet Co. stock logo
PODD
Insulet
$1.00$1.15+$0.15$1.39$582.02 million$597.50 million
2/13/2025Q4 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.50$0.45-$0.05$0.38$1.10 billionN/A
1/30/2025Q2 2025
ResMed Inc. stock logo
RMD
ResMed
$2.29$2.43+$0.14$2.34$1.27 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Insulet Co. stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.120.90%+7.63%23.79%13 Years
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
N/AN/AN/AN/AN/A

Latest SWAV, RMD, DXCM, and PODD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%5/8/20255/8/20256/12/2025
1/30/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%2/13/20252/13/20253/20/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.59
1.47
1.28
Insulet Co. stock logo
PODD
Insulet
1.21
3.68
2.80
ResMed Inc. stock logo
RMD
ResMed
0.13
3.33
2.29
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
0.97
13.81
12.61

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Insulet Co. stock logo
PODD
Insulet
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
95.35%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Insulet Co. stock logo
PODD
Insulet
0.47%
ResMed Inc. stock logo
RMD
ResMed
0.71%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
3.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
7,600392.11 million389.60 millionOptionable
Insulet Co. stock logo
PODD
Insulet
2,60070.23 million69.82 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
8,160146.87 million145.82 millionOptionable
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
1,46837.54 million36.27 millionOptionable

Recent News About These Companies

Shockwave E8 Peripheral IVL Catheter Launched

New MarketBeat Followers Over Time

Media Sentiment Over Time

DexCom stock logo

DexCom NASDAQ:DXCM

$71.66 +0.88 (+1.24%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$71.64 -0.02 (-0.03%)
As of 04/25/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Insulet stock logo

Insulet NASDAQ:PODD

$260.71 +1.33 (+0.51%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$269.05 +8.34 (+3.20%)
As of 04/25/2025 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

ResMed stock logo

ResMed NYSE:RMD

$235.79 -0.31 (-0.13%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$238.22 +2.43 (+1.03%)
As of 04/25/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Shockwave Medical stock logo

Shockwave Medical NASDAQ:SWAV

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.